Bristol Myers Squibb Co. closed 3.76% short of its 52-week high of $61.10, which the company achieved on January 27th.

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) saw some unusual options trading on Tuesday. Traders acquired 46,473 call options on the company. This represents an increase of approximately 61% ...

We recently published a list of Dividend Stock Portfolio For Income: Top 10 Stocks to Buy. In this article, we are going to ...

Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...

In other words, for those looking for "forever stocks," it's not a bad idea to look in this sector. And even with a modest ...

Sandra Leung began her legal career prosecuting homicides, a formative experience that she once said taught her "to make ...

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...

Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics ...

Stock analysts at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for Bristol-Myers Squibb in a note ...

Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a ...

Squibb announced new five-year results from the POETYK PSO long-term extension, LTE, trial of Sotyktu treatment in adult ...

Shares of Bristol Myers Squibb Co. BMY slid 1.43% to $57.38 Wednesday, on what proved to be an all-around mixed trading ...